AXON Axon Enterprise Inc

HAMILTON, Bermuda, Nov. 1, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at three investor conferences:

• November 8 at 3:30 p.m. MST at the 25th Annual Credit Suisse Healthcare Conference
• November 16 at 1:20 p.m. GMT at the Jefferies 2016 London Healthcare Conference
• November 29 at 12:30 p.m. EST at the 28th Annual Piper Jaffray Healthcare Conference

A simultaneous webcast will be available in the Investors section of Axovant's website at www.axovant.com. A replay will be available for 30 days following each conference.

About Axovant
Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of this condition.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-sciences-to-present-at-upcoming-investor-conferences-300355228.html

SOURCE Axovant Sciences Ltd.